Abstract: The formation of a nodule within a congenital melanocytic nevus (CMN) raises concerns about possible melanoma. Most new nodular growths that develop during childhood, however, are benign proliferative nodules (PN); melanoma is very rare. The distinction of melanoma from PN can at times be difficult clinically and histopathologically, requiring ancillary molecular tests for diagnosis. Although the application of molecular methods has revealed new insights into the mutational and genomic landscape of childhood melanomas, little is known about epigenetic events that may drive the growth of a melanoma or PN in a CMN. In this study we compared the expression of H3K27me3, a key regulator in chromatin remodelling-controlled transcription, in PNs and pediatric nodular melanomas arising within medium-sized to large CMN by immunohistochemistry. Significant loss of H3K27me3 expression was seen in 4 of 5 melanomas, but not in any of the 20 PNs. This observation suggests that epigenetic events likely play a role in the pathogenesis of melanoma developing in the dermis or subcutis of CMN. Furthermore, assessing for H3K27me3 expression by immunohistochemistry may be diagnostically useful for problematic cases.
N ew nodules may form within a congenital melanocytic nevus (CMN). The majority of these are benign proliferative nodules (PNs), but on rare occasion a melanoma may develop within the dermal or subcutaneous compartment of a large melanocytic nevus. [1] [2] [3] [4] The incidence with which PNs develop has been estimated to range from 3% to 20% in giant CMN. 1, 5, 6 The incidence of cutaneous melanoma arising in CMN of all sizes and numbers considered together is lower, of the order of <1% to 3%. [7] [8] [9] [10] However, this varies substantially with the severity of the clinical phenotype.
In most children a PN can reliably be distinguished from melanoma by clinicopathologic correlation. Clinically, a PN typically differs from melanoma by uniformity of color and outline, a tendency to stabilize, and lower likelihood to ulcerate. Histopathologically, the melanocytes of a PN tend to blend in with those of the background nevus, but nonetheless form a microscopically distinct nodule due to their hypercellularity. There is a range of histopathologic appearances of PNs from small to large epithelioid to fusiform, blue or Spitz nevus-like, pigmented or amelanotic. 6, 11 Sometimes a nodule may display mesenchymal features under the microscope. 12 In general, melanomas are more abruptly demarcated from the surrounding nevus, display a higher degree of nuclear atypia, and many more tumor cells are seen in mitosis. 11 In melanoma, there may be apoptotic bodies or even frank tumor necrosis.
Some melanomas display marked nuclear pleomorphism, numerous mitoses, and tumor necrosis, making their recognition as a malignancy by light microscopic examination straightforward. However, especially on a partial biopsy, the distinction of a PN from melanoma can be difficult, in particular when the level of atypia and number of mitoses are in a gray zone, that is, at a level that can be seen both in association with a benign as well as a malignant tumor, or the nodule has spitzoid or undifferentiated mesenchymal features. In those cases, ancillary genetic studies may assist in the diagnostic workup. In the past decade, cytogenetic analysis has emerged as a useful adjunct method for the distinction of melanoma from PN. 11, 13 Melanomas tend to show segmental chromosomal gains and/or losses involving different chromosomes while PNs either may not contain any detectable cytogenetic aberrations or may carry whole chromosome gains or losses, 11,13-15 but there are rare exceptions. 16 Furthermore, interpretation of these techniques typically requires some experience or expertise in assessing cytogenetics in melanocytic neoplasia.
Much has been learned in recent years about the mutational landscape of melanomas. 17 Melanomas in adults, the vast majority of which arise at the dermalepidermal junction, tend to be rich in mutations, with variations in mutation type and number depending on anatomic site and extent of sun exposure. 18, 19 Preliminary evidence of mutational analyses of childhood melanomas indicates that conventional (adult-type) melanomas affecting the skin surface of children also carry ultraviolet (UV) mutations and commonly harbor BRAFV600 mutations. 20 However, pediatric melanomas associated with CMN tend to lack UV mutations and have a lower mutational burden 20 (K.J.B., unpublished data). Given the distinct clinical setting and behavior (lack of UV exposure, onset of rapid tumor growth) we speculated that epigenetic events may play a role in the development of subepidermal childhood melanomas arising in CMN.
The purpose of this study was to explore the possible role of epigenetic changes in subsurface nodular melanomas arising in CMN. As a marker for epigenetic changes we chose immunohistochemical (IHC) expression of H3K27me3. 21, 22 This marker was chosen because the assay conditions are well established in our laboratory, and it has been tested on melanomas before.
MATERIALS AND METHODS
The work in this study was approved by the institutional review boards of both institutions. Twenty benign PMs and 5 nodular melanomas that arose in the dermal component of a CMN during childhood were selected and analyzed immunohistochemically. We also evaluated 10 primary melanomas from adults. Sections (5-mm thick) were taken from formalin-fixed and paraffinembedded tissue.
An automated IHC system (Leica Bond, polymer) was used, with a commercially available antibody to H3K27me3 (clone C36B11; Cell Signaling).
Labeling was scored according to the percentage of immunoreactive tumor cells per total number of tumor cells: 0 = no staining; 1+ = 1% to 25% of tumor cells are positive; 2+ = 26% to 50% of tumor cells are positive; 3+ = 51% to 75% of tumor cells positive; and 4+ = 76% to 100% of tumor cells are positive.
Genomic Analysis
Sequence analysis was performed on all 5 melanomas for clinical purposes. Two tumors were analyzed by FoundationOne; 2 tumors were analyzed at Imperial College in London, UK; 1 tumor was analyzed at the Northwestern University Feinberg School of Medicine in Chicago, IL, with the PGM ion torrent 50 gene cancer panel (ThermoFisher, Waltham, MA).
The 5 melanomas were also analyzed cytogenetically. Melanoma case 1 was analyzed by FoundationOne. Case 1 and 2 were analyzed by SNP array (OncoScan). In case 3, array comparative genomic hybridization was performed as per the manufacturer's instructions, using Roche Nimblegen 135 K oligonucleotide arrays and a sexmatched commercial pooled control. Cases 4 and 5 were analyzed by fluorescent in situ hybridization analysis, using probes for 6p, 6q, 6cent, 11q, and 8q. 23, 24 
RESULTS

Clinical Findings
Of the 20 children with PNs, 11 were female and 9 were male. The mean age was 4.2 years; the median age was 2 years. Of the 5 children with a nodular melanoma arising in a CMN, 3 were girls and 2 of them were boys. Three of the children with melanoma also had preceding or concurrent PNs at other sites. Two children died of metastatic melanoma. One of them was a boy (case 2) who died in his second year of life. He had a primary nodular melanoma that arose in perianal soft tissue in association with a giant bathing trunk CMN (measuring > 40 cm in largest dimension, 160 additional nevi). The other child with a lethal melanoma was a girl (case 3). She developed a nodular melanoma in a large CMN on the scalp (20 cm projected adult size; multiple other melanocytic nevi from birth) at the age of 6 years. She died at age 7. The 3 other children are still alive, but with limited follow-up. One of them is a girl who developed a nodular melanoma on the scalp at the age of 8 years (case 1). Her melanoma arose in a CMN measuring 9Â 8 cm, with a predicted adult size of approximately 10 cm. The girl is still alive without evidence of disease 1 year after surgical removal of the primary tumor. The fourth child with a nodular melanoma is an infant girl. Her recently diagnosed melanoma was congenital and associated with a CMN of the scalp measuring 12 cm in greatest dimension. The sentinel lymph node and 2 of 28 nonsentinel regional lymph nodes were positive for tumor deposits. The girl is alive with follow-up of 5 months (October 2016). One patient is a teenage boy who developed a subsurface nodular melanoma at age 15 on the scalp at the site of a previously partially excised CMN measuring 10Â 20 cm. He also had multiple other nevi. One of his regional lymph nodes was found to be positive for metastatic melanoma. He is currently alive and well with a follow-up of approximately 1 year.
Pathologic Findings
The histopathologic findings of the PNs are summarized in Table 1 and representative examples are illustrated in Figures 1-3 . Each PN was histopathologically characterized by a hypercellular expansile melanocyte proliferation in the dermis. Ten lesions were amelanotic. Focal melanin pigment was present in 6 nodules; 4 nodules were heavily pigmented throughout. Two of them resembled an epithelioid blue nevus. The dominant cell type in 12 cases was round to oval (epithelioid) in morphology (Fig. 2) . In 5 cases there was a mix of both spindle and epithelioid-shaped melanocytes. Three tumors were predominantly fusiform. Two tumors were associated with stromal sclerosis.
All melanomas presented as nodular dermal and/or subcutaneous tumors without associated in situ melanoma. The tumor cells displayed epithelioid cell features ( Table 2 , Figs. 4-7) . In 2 cases they had a small round blue cell (melanoblastic) appearance with minimal visible cytoplasm (Fig. 4) . In 2 cases the tumor cells were small to intermediate in size with enlarged nuclei and small amounts of pink cytoplasm. One of them contained a subpopulation of tumor cells with melanin pigment (Fig. 5) ; the other was predominantly amelanotic (Fig. 6 ).
One case was composed of amelanotic large pleomorphic epithelioid tumor cells ( Fig. 7) with pink cytoplasm. Mitoses were frequent (mitotic rate > 4/mm 2 ) in all but 1 case. The mitotic rate of the large epithelioid cell nodule of the 15-year-old boy (case 5) had a mitotic rate of only 1/mm 2 .
IHC Findings
All 20 PNs homogenously expressed H3K27me3. Nuclear expression was seen throughout the nodule as well as in the adjacent cells of the melanocytic nevus outside of the PN (Figs. 1-3) . Positive labeling was seen in >80% of lesional cells of all 20 PNs.
Marked reduction in labeling for H3K27me3 was seen in 4 prepubertal pediatric nodular melanomas that arose in a CMN (Table 2 , Figs. 4-6 ), whereas the expression of H3K27me3 was retained in the adjacent nevus and normal tissue. Among these 4 tumors, the extent of loss of labeling for H3K27me3 within the melanoma ranged from nearly complete (Figs. 4, 6 ) to approximately half of the tumor cells (Fig. 5) . One nodular melanoma (case 5, Table 2 ), which developed on the scalp of a teenager, showed only minimal (B10%) loss H3K27me3 expression (Fig. 7) .
All 10 adult melanomas retained expression of H3K27me3, but partial loss of labeling (<50% of tumor cells were immunonegative) was seen in 1 acral melanoma (not shown).
Molecular Aberrations of Melanomas
The molecular aberrations detected in the nodular melanomas are summarized in Table 2 . Three of the 5 tumors harbored NRAS mutations: 2 had an NRASQ61R, 1 an NRASG13R mutation. In 2 cases (cases 3 and 5) Sanger sequencing analysis of NRAS and BRAF confirmed NRASQ61R and BRAF wild-type mutation status in 1 case (case 3). The other tumor (case 5) was confirmed to have wild-type mutation status for both NRAS and BRAF. In 3 cases, targeted next-generation sequencing analysis was performed, which failed to reveal any mutation in case 2, detected a single NRASQ61R mutation in case 1, and documented a single NRASG13R mutation in case 4. All 5 melanoma cases had segmental chromosomal copy number aberrations. Genomic analysis documented numerous small segmental gains and losses involving different chromosomes in 3 of the 4 melanomas (cases 1, 3, 4, and 5). One lethal melanoma (case 2) contained only a single segmental gain of 6p by SNP array analysis. This melanoma was found to have a RAD18-BRAF fusion and small deletions involving PIK3CA, PIK3R1, and CTNNB1 by next-generation sequence analysis (FoundationOne).
DISCUSSION
Much has been learned about the mutational landscape of melanomas. 17 The majority of melanomas in adults carry a high mutational burden, especially those tumors associated with chronic UV damage. 18, 19 A recent study on a limited number of "childhood and adolescent" melanomas also identified a high number of mutations in conventional melanomas of teenagers and young adults (age range, 11 to 20 y; median age = 16 y), with frequent BRAFV600 and TERT promoter mutations. 20 In contrast, each of the 3 melanomas associated with a CMN, which occurred in children younger than 5 years of age, contained an activating NRASQ61R mutation and no TERT promoter mutation. 20 It is of interest that the mutational burden of 2 of the 3 CMN melanomas was very low. 20 However, it is difficult to draw conclusions from this study about melanomas associated with CMN due to the small number of cases (only 3) and lack of detail about the pathology of the melanomas. 20 It is not clear whether the melanomas associated with CMN developed at the dermal-epidermal junction or in the dermis/subcutis. The authors also failed to specify the phenotype of patients with the congenital nevi.
We know, however, from prior studies that NRAS mutations are associated with melanomas of large CMN. 2, 25, 26 Three of the 5 melanomas tested in this series also had an NRAS mutation.
The apparent paucity of the total number of mutations and the commonly observed rapid clinical growth of melanoma in early childhood made us suspect that epigenetic drivers may play a role in their pathogenesis. We also reasoned that epigenetic changes relevant in the pathogenesis of melanomas are likely different from benign PNs and could potentially be used for diagnostic purposes.
Among epigenetic events, posttranslational modifications of the N-terminal cores of histones, such as by methylation, influences chromatin configuration and thereby modulates accessibility of transcription factors and transcriptional activity. 21, 27, 28 H3K27 trimethylation (H3K27me3) is a well-known epigenetic gene silencer that can repress transcription. Polycomb repressive complexes 2 (PRC2) containing enhancer of zeste (EZH) 2, a methyltransferase and core component of PRC2, are responsible for trimethylation of H3K27. 21 Aberrant expression of H3K27me3 has been found in different types of cancers and has been correlated with prognosis. 22, 29 H3K27me3 expression levels can be assessed in formalinfixed and paraffin-embedded tissues by IHC and its expression pattern has recently been found to be useful for the distinction of malignant peripheral nerve sheath tumors from histologic mimics, including melanomas. 30, 31 We explored the role of epigenetic events in childhood melanomas arising in CMN by comparing H3K27me3 expression in benign PNs and nodular melanomas of medium-sized and large CMN.
Despite the rarity of bona-fide nodular melanomas arising in CMN of young children, we were able to analyze 5 tumors. Four of 5 tumors showed marked reduction in labeling of H3K27me3, from approximately half of the tumor cells in 1 case to >80% in the other 3. One tumor showed minimal (approximately 10%) loss of labeling. It differed from the other tumors histopathologically by a large epithelioid cell phenotype, low mitotic rate, and clinically by its occurrence in a teenager. In contrast to the majority of melanomas, all PNs retained expression of H3K27me3 expression in >80% of tumor cells.
The loss of H3K27me3 staining in melanomas of young children is of interest, as prior studies on H3K27me3 expression in melanomas suggested that this marker is typically retained. 30, 31 Those melanomas, however, were from adults, with no documentation of an associated melanocytic nevus. Future studies of a larger set of different types melanomas from different age groups are needed to determine the expression pattern of H3K27me3 and its significance in various types of melanomas and at different clinical stages.
In conclusion, we report herein reduction of H3K27me3 expression in 4 of 5 nodular melanomas arising in the subepithelial compartment of a CMN during childhood. In contrast, H3K27me3 expression was retained or only mildly reduced in 20 benign PNs and the nevus cells adjacent to the melanoma nodules. These observations document for the first time that H3K27me3 expression can be markedly reduced in primary cutaneous melanoma. They indicate a likely role for epigenetic events in the pathobiology of at least some pediatric nodular melanomas developing in CMN. Our results also suggest that H3K27me3 expression has the potential to become an ancillary diagnostic tool for the distinction of a melanoma from an unusual PN. As no major reduction in labeling for H3K27me3 was seen in any of the 20 benign PNs examined herein, loss of labeling for this marker should make one hesitate establishing a diagnosis of PN. In contrast, retention of H3K27me3 expression can be seen in both PN and melanoma. Examination of a larger set of cases is necessary to assess the biological significance of H3K27me3 expression in melanomas and its potential diagnostic value.
